Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo

Belén Borrego, Gema Lorenzo, Josué D. Mota-Morales, Horacio Almanza-Reyes, Francisco Mateos, Elena López-Gil, Nuria de la Losa, Vasily A. Burmistrov, Alexey Nikolaevich Pestryakov, Alejandro Brun, Nina Bogdanchikova

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In this work we have tested the potential antiviral activity of silver nanoparticles formulated as Argovit™ against Rift Valley fever virus (RVFV). The antiviral activity of Argovit was tested on Vero cell cultures and in type-I interferon receptor deficient mice (IFNAR -/- mice) by two different approaches: (i) different dilutions of Argovit were added to previously infected cells or administrated to animals infected with a lethal dose of virus; (ii) virus was pre-incubated with different dilutions of Argovit before inoculation in mice or cells. Though the ability of silver nanoparticles to control an ongoing RVFV infection in the conditions tested was limited, the incubation of virus with Argovit before the infection led to a reduction of the infectivity titers both in vitro and in vivo. These results reveal the potential application of silver nanoparticles to control the infectivity of RVFV, which is an important zoonotic pathogen.

Original languageEnglish
Pages (from-to)1185-1192
Number of pages8
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume12
Issue number5
DOIs
Publication statusPublished - 1 Jul 2016

Fingerprint

Rift Valley fever virus
Viruses
Silver
Nanoparticles
Antiviral Agents
Interferon alpha-beta Receptor
Vero Cells
Zoonoses
Virus Diseases
Dilution
Cell Culture Techniques
Interferons
Pathogens
Infection
Cell culture
In Vitro Techniques
Animals

Keywords

  • Antivirals
  • In vivo infection
  • Rift Valley fever virus
  • Silver nanoparticles

ASJC Scopus subject areas

  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Borrego, B., Lorenzo, G., Mota-Morales, J. D., Almanza-Reyes, H., Mateos, F., López-Gil, E., ... Bogdanchikova, N. (2016). Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 12(5), 1185-1192. https://doi.org/10.1016/j.nano.2016.01.021

Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo. / Borrego, Belén; Lorenzo, Gema; Mota-Morales, Josué D.; Almanza-Reyes, Horacio; Mateos, Francisco; López-Gil, Elena; de la Losa, Nuria; Burmistrov, Vasily A.; Pestryakov, Alexey Nikolaevich; Brun, Alejandro; Bogdanchikova, Nina.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 12, No. 5, 01.07.2016, p. 1185-1192.

Research output: Contribution to journalArticle

Borrego, B, Lorenzo, G, Mota-Morales, JD, Almanza-Reyes, H, Mateos, F, López-Gil, E, de la Losa, N, Burmistrov, VA, Pestryakov, AN, Brun, A & Bogdanchikova, N 2016, 'Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo', Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 12, no. 5, pp. 1185-1192. https://doi.org/10.1016/j.nano.2016.01.021
Borrego, Belén ; Lorenzo, Gema ; Mota-Morales, Josué D. ; Almanza-Reyes, Horacio ; Mateos, Francisco ; López-Gil, Elena ; de la Losa, Nuria ; Burmistrov, Vasily A. ; Pestryakov, Alexey Nikolaevich ; Brun, Alejandro ; Bogdanchikova, Nina. / Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2016 ; Vol. 12, No. 5. pp. 1185-1192.
@article{1007f9a200554e73ae57c95b8cf684b5,
title = "Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo",
abstract = "In this work we have tested the potential antiviral activity of silver nanoparticles formulated as Argovit™ against Rift Valley fever virus (RVFV). The antiviral activity of Argovit was tested on Vero cell cultures and in type-I interferon receptor deficient mice (IFNAR -/- mice) by two different approaches: (i) different dilutions of Argovit were added to previously infected cells or administrated to animals infected with a lethal dose of virus; (ii) virus was pre-incubated with different dilutions of Argovit before inoculation in mice or cells. Though the ability of silver nanoparticles to control an ongoing RVFV infection in the conditions tested was limited, the incubation of virus with Argovit before the infection led to a reduction of the infectivity titers both in vitro and in vivo. These results reveal the potential application of silver nanoparticles to control the infectivity of RVFV, which is an important zoonotic pathogen.",
keywords = "Antivirals, In vivo infection, Rift Valley fever virus, Silver nanoparticles",
author = "Bel{\'e}n Borrego and Gema Lorenzo and Mota-Morales, {Josu{\'e} D.} and Horacio Almanza-Reyes and Francisco Mateos and Elena L{\'o}pez-Gil and {de la Losa}, Nuria and Burmistrov, {Vasily A.} and Pestryakov, {Alexey Nikolaevich} and Alejandro Brun and Nina Bogdanchikova",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.nano.2016.01.021",
language = "English",
volume = "12",
pages = "1185--1192",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo

AU - Borrego, Belén

AU - Lorenzo, Gema

AU - Mota-Morales, Josué D.

AU - Almanza-Reyes, Horacio

AU - Mateos, Francisco

AU - López-Gil, Elena

AU - de la Losa, Nuria

AU - Burmistrov, Vasily A.

AU - Pestryakov, Alexey Nikolaevich

AU - Brun, Alejandro

AU - Bogdanchikova, Nina

PY - 2016/7/1

Y1 - 2016/7/1

N2 - In this work we have tested the potential antiviral activity of silver nanoparticles formulated as Argovit™ against Rift Valley fever virus (RVFV). The antiviral activity of Argovit was tested on Vero cell cultures and in type-I interferon receptor deficient mice (IFNAR -/- mice) by two different approaches: (i) different dilutions of Argovit were added to previously infected cells or administrated to animals infected with a lethal dose of virus; (ii) virus was pre-incubated with different dilutions of Argovit before inoculation in mice or cells. Though the ability of silver nanoparticles to control an ongoing RVFV infection in the conditions tested was limited, the incubation of virus with Argovit before the infection led to a reduction of the infectivity titers both in vitro and in vivo. These results reveal the potential application of silver nanoparticles to control the infectivity of RVFV, which is an important zoonotic pathogen.

AB - In this work we have tested the potential antiviral activity of silver nanoparticles formulated as Argovit™ against Rift Valley fever virus (RVFV). The antiviral activity of Argovit was tested on Vero cell cultures and in type-I interferon receptor deficient mice (IFNAR -/- mice) by two different approaches: (i) different dilutions of Argovit were added to previously infected cells or administrated to animals infected with a lethal dose of virus; (ii) virus was pre-incubated with different dilutions of Argovit before inoculation in mice or cells. Though the ability of silver nanoparticles to control an ongoing RVFV infection in the conditions tested was limited, the incubation of virus with Argovit before the infection led to a reduction of the infectivity titers both in vitro and in vivo. These results reveal the potential application of silver nanoparticles to control the infectivity of RVFV, which is an important zoonotic pathogen.

KW - Antivirals

KW - In vivo infection

KW - Rift Valley fever virus

KW - Silver nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84962330745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962330745&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2016.01.021

DO - 10.1016/j.nano.2016.01.021

M3 - Article

VL - 12

SP - 1185

EP - 1192

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 5

ER -